10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.
The collaboration marks 10x's first clinical research initiative to extend beyond solid tumors into blood cancers, and builds on 10x's work to generate evidence for the clinical potential of its single cell and spatial products in oncology diagnostics.
"Across cancer care, we have more effective therapies than ever, and too little insight into which patient will actually benefit from which one," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Single cell and spatial biology let us look directly at the biology that drives treatment response, whether it's in a tumor or in the blood, and we believe that's the missing foundation for precision oncology. We're excited to work with Fred Hutch on this research."
This collaboration builds on 10x's announced collaborations with leading hospitals and institutes, and, together with 10x's planned CLIA-certified laboratory, builds the scientific and operational foundation for potential future diagnostic applications in oncology and autoimmune disease. As part of this effort, 10x and Fred Hutch also plan to build a framework for future clinical reporting, defining how single cell and spatial features could support treatment planning in patients with cancer.